Hepatitis B disease is a relatively complex disease, with over 30 million chronic hepatitis B patients in China, and the hepatitis B virus is currently impossible to completely remove, but can only be suppressed. The disease brings great pain and burden to the lives of patients. The following seven major issues are of most concern to patients with chronic hepatitis B. Treatment time and treatment cost According to the internet search results the time of hepatitis B antiviral treatment is one of the most important concerns for patients. The expert recommendation degree is five stars. The ultimate goal of hepatitis B antiviral treatment is to reduce and minimize the occurrence of hepatitis B developing into cirrhosis and liver cancer. To completely suppress hepatitis B virus and achieve the goal, the key is to achieve long-term adherence to standardized treatment. However, patients must realize that only a small percentage of patients can stop the medication early, and most patients should be fully prepared for a “protracted battle” when they start treatment. The second most important concern is the cost of treatment, which is directly related to the ability to adhere to long-term standardized antiviral treatment. Research shows that 80% of hepatitis B patients have a monthly income of less than 3,000 yuan, while oral antiviral drugs cost from 500 to 2,000 yuan per month. Patients should choose oral antiviral drugs that can adhere to long-term treatment, so as to avoid interruption of treatment due to financial burden. Patients with hepatitis B should consider in the long run how they can reduce disease progression, reduce the occurrence of cirrhosis and liver cancer, and at the same time reduce the economic burden is the most important. Efficacy and side effects Second, the efficacy of hepatitis B antiviral therapy and the need for regular monitoring are also issues of great concern to patients. Although hepatitis B antiviral therapy cannot directly eliminate the hepatitis B virus, it can suppress the virus to a manageable and low level. Many patients compare the efficacy of various medications by switching between them during treatment in the hope of achieving the best possible outcome. However, because hepatitis B disease is a long-term disease, it is important for patients to observe the safety of the drug in addition to its efficacy when choosing a drug. Currently, several oral antiviral drugs, including lamivudine and adefovir, have been used in clinical practice, all of which are effective in suppressing the hepatitis B virus. Lamivudine is fast-acting and has been proven to slow down the progression of liver cancer and cirrhosis; it has been on the market for the longest time, with 10 years of clinical validation, and has the widest application population and proven safety. The principle of three less ranked fifth, three less that is, the reduction of hepatitis B to cirrhosis and liver cancer, the reduction of adverse effects of long-term drug treatment, and the reduction of the economic burden of long-term treatment. This is the principle of comprehensive evaluation of drugs and the benefits that drugs can bring to hepatitis B friends. Many patients have misconceptions about the long-term nature of the disease and the standard treatment in the treatment process, which leads to confusion in choosing drugs, thinking that expensive drugs are good drugs, which will directly affect the future treatment path. The three less principles evaluate drugs comprehensively from 3 perspectives, rather than blindly focusing on one point. The absence of one of the three clarifies the initial drug selection principle for patients. The reason why the expert recommendation degree is 5 stars is because following the three less principles is the guarantee that patients can adhere to long-term standardized antiviral therapy, which is a summary of experience after 10 years of hepatitis B antiviral treatment course, and has guiding significance for hepatitis B patients in treatment! Monitoring and drug resistance In recent years, as more and more oral nucleoside analogues have been marketed and the time spent in clinical application has accumulated, more and more patients have become concerned about drug resistance. In fact, drug resistance is common to all oral antiviral therapy drugs and is something that any oral antiviral drug may have to face. As long as patients are able to visit the hospital every three months to have their HBV DNA and liver function tested, doctors will easily detect early viral mutations. Of course, testing is not only for drug resistance, but adverse drug reactions can also be detected in time during testing. Moreover, drugs that can inhibit the replication of drug-resistant viruses are now available, and as long as the mutations are detected early, the disease can be controlled by early changes in treatment regimen. The hepatitis B patients should face the drug resistance with a positive attitude, without excessive fear, as long as the treatment under the guidance of the doctor is completely able to solve the problem of virus resistance.